Login
CRESCENT BIOPHARMA, INC. logo

CRESCENT BIOPHARMA, INC.

crescentbiopharma.com

What Do They Do?

Develops experimental therapies for people with solid tumors, including an antibody designed to bind two targets and drug-carrying antibodies.

How Do They Make Money?

The company earns money by licensing internally developed drug candidates. Licensees pay upfront, may owe additional payments when clinical, regulatory or sales milestones occur, and owe royalties on commercial product sales.

FY2025 revenue

Who Are Their Customers?

Revenue came from a China-based customer licensing drug candidates.

Do Revenues Turn Into Profits?

No. It lost $153.9M in FY2025.

Operating income, FY2025
−1408% of revenue
▼ −281% (Loss) vs FY2024 (−$40M)
Net income, FY2025
−1420% of revenue
▼ −306% (Loss) vs FY2024 (−$37.9M)
Free cash flow, FY2025
−668% of revenue
▼ −133% (Loss) vs FY2024 (−$31.1M)

How Are They Changing?

Since the FY2025 annual report
  • Jul 14, 2026 Priced a public offering of shares and pre-funded warrants The offering was expected to yield approximately $115.9 million in net proceeds.

Growing. Revenue grew 9.4x in 4 years, from $1.2M in FY2021 to $10.8M in FY2025, about 75% a year.

From glycomimetic drugs to antibody therapies The earlier report focused on glycomimetic drugs for cancer and inflammatory diseases; the latest focuses on antibody therapies and antibody-drug conjugates for solid tumors.

Who Do They Compete With?

Competes with Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Summit Therapeutics, BioNTech, LaNova Medicines, 3SBio, Pfizer, Compass Therapeutics, and Henlius

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support